Correspondence

Divergent evolution of vitamin B<sub>9</sub> binding underlies Juno-mediated adhesion of mammalian gametes

Ling Han<sup>1,3</sup>, Kaoru Nishimura<sup>1,2</sup>, Hamed Sadat Al Hosseini<sup>1</sup>, Enrica Bianchi<sup>1</sup>, Gavin J. Wright<sup>2</sup>, and Luca Jovine<sup>1,*</sup>

The interaction between egg and sperm is the first necessary step of fertilization in all sexually reproducing organisms. A decade-long search for a protein pair mediating this event in mammals culminated in the identification of the glycosylphosphatidylinositol (GPI)-anchored glycoprotein Juno as the egg plasma membrane receptor of sperm Izumo1<sup>[1,2]</sup>. The Juno–Izumo1 interaction was shown to be essential for fertilization since mice lacking either gene exhibit sex-specific sterility, making these proteins promising non-hormonal contraceptive targets<sup>[1,3]</sup>. No structural information is available on how gamete membranes interact at fertilization, and it is unclear how Juno — which was previously named folate receptor (FR) 4, based on sequence similarity considerations — triggers membrane adhesion by binding Izumo1<sup>1</sup>. Here, we report the crystal structure of Juno and find that the overall fold is similar to that of FRα and FRβ but with significant flexibility within the area that corresponds to the rigid ligand-binding site of these bona fide folate receptors. This explains both the inability of Juno to bind vitamin B<sub>9</sub>/folic acid<sup>[1]</sup>, and why mutations within the flexible region can either abolish or change the specificity of this interaction. Furthermore, structural similarity between Juno and the cholesterol-binding Niemann-Pick disease type C1 protein (NPC1) suggests how the modified binding surface of Juno may recognize the helical structure of the amoно-terminal domain of Izumo1. As Juno appears to be a mammalian innovation, our study indicates that a key evolutionary event in mammalian reproduction originated from the neofunctionalization of the vitamin B<sub>9</sub>-binding pocket of an ancestral folate receptor molecule.

To gain insights into how Juno recognizes Izumo1, we expressed the complete ectodomain of mouse Juno (residues G20–A221) as a soluble protein in glycosylation-impaired mammalian cells (see Supplemental Experimental Procedures). Following enzymatic trimming of N-glycans, affinity-purified Juno behaved as a monomer by size-exclusion chromatography (Figure S1A,B) and yielded a ~10 µm thick crystal that diffracted to 2.7 Å resolution (Figure S1C). The structure of Juno was solved by molecular replacement and refined to R = 23.3%, R<sub>free</sub> = 24.8% (Figure S1D–F and PDB ID 5EJN).

Juno consists of nine α-helices and six short β-strands (Figure 1A and Figure S2A), which adopt the same fold of FRα and FRβ<sup>[4,5]</sup> and riboflavin-binding protein (RBP)<sup>[6]</sup>. The bulk of the structure, including four core α-helices and seven disulfide bonds, can be superimposed onto the ligand-bound form of human FRα<sup>[4]</sup> and FRβ<sup>[5]</sup> with root mean square deviations (RMSD) of 1.4 Å and 1.6 Å over 166 and 167 residues, respectively (Figure 1B). Although glycosylation at N73 is important for secretion of Juno (Figure S1G, lane 1), there is no electron density for the loop carrying the corresponding GlcNAc, suggesting that this conserved carbohydrate affects protein solubility rather than folding. A crystal contact, however,
Magazine

Current Biology

fixes the position of the N-glycan at N185 (Figure S1F), which is neither conserved (Figure S2A) nor required for secretion (Figure S1G, lane 2).

Despite their overall similarity, there are striking local differences between the structure of Juno and that of FRs and RfBP. Whereas in the latter proteins three highly ordered loops generate a deep binding pocket for the respective ligands [4–6], the corresponding regions of Juno are either largely disordered (loops 1 and 3) or adopt a very different conformation (loop 2) (Figure 1B and Figure S2A).

Notably, the structured nature of these loops in FRs does not depend on vitamin B\textsubscript{12} binding because they are also visible in the unbound forms of FR\textalpha and FR\textbeta [5]. Taken together with sequence alignments (Figure S2A), these observations suggest that — in addition to key amino acid substitutions such as D103A [1,4] — structural disorder or displacement of conserved pocket residues important for ligand recognition in FR\textalpha [4] contribute to the inability of Juno to bind vitamin B\textsubscript{12}. These amino acids include FR\textalpha F84 and G159–W162, whose counterparts in loops 1 and 3 of Juno are completely disordered (Figure S2A), as well as FR\textbeta R128, which in Juno is shifted by ~13 Å because of the different conformation of the loop 2 region (Figure 1B).

Although the Juno–Izumo1 interaction is conserved in mammals [1], it demonstrates some specificity across species. For example, mouse Juno does not bind human Izumo1, as assessed by avidity-based extracellular interaction screen (AVEXIS), a sensitive extracellular protein interaction assay (Figure 1C) [7]. Interestingly, the sequence identity between mouse and human Juno (70% overall) drops in loops 1 and 2, as well as in the disordered carboxy-terminal half of loop 3 (53%, 12% and 47%, respectively; Figure S2A). To test whether these regions of Juno are involved in its species-specific interaction with Izumo1, we designed a series of mouse Juno protein variants where loops 1–3 were individually replaced with the corresponding human sequences (Figure S2A). Additionally, an N185S mutant was also produced to assess whether the non-conserved N-glycan of Juno, which is located close to loop 2 (Figure 1A,B), is important for mouse Izumo1 recognition. Using AVEXIS we showed that, whereas loop 2 and N185S mutant mouse Juno proteins still bound mouse Izumo1, binding was lost upon humanization of loop 1. Moreover, humanization of loop 3 altered the species specificity of mouse Juno, so that it additionally bound human Izumo1 (Figure 1C). Together, these results suggest that the area delimited by loops 1 and 3 mediates binding of Juno to Izumo1, and that the flexible parts of these loops may become ordered upon protein–protein interaction.

Although the structure of Izumo1 is unknown, its amino-terminal Juno-binding region has been shown to be helical [8]. Notably, loops 1 and 3 of Juno surround a groove in the protein surface (Figure 1D), and the corresponding region of NPC1 [9] — a distant structural homologue of Juno (Figure S2B) — accommodates an additional \alpha-helix (Figure 1E). Based on these considerations, it can be hypothesized that docking of an \alpha-helix of Izumo1 onto the groove of Juno may underlie adhesion of the gamete plasma membranes.

Whereas FR homologues are found in all vertebrate classes, Juno appears restricted to mammals. According to this observation, our studies suggest that the molecular basis of mammalian gamete recognition evolved from an ancestral FR that lost the ability to bind vitamin B\textsubscript{12} but gained the ability to recognize Izumo1.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes two figures and experimental procedures, and can be found with this article online at http://dx.doi.org/10.1016/j.cub.2015.12.034.

**AUTHOR CONTRIBUTIONS**

Conceptualization, K.N., G.J.W. and L.J.; methodology, L.H., K.N., L.J.; validation, E.B.; formal analysis, K.N., L.J.; investigation, L.H., K.N., H.S.A.H., E.B.; data curation, K.N., L.J.; writing – original draft, L.H., K.N., L.J.; writing – review and editing, L.H., K.N., H.S.A.H., E.B., G.J.W., L.J.; visualization, K.N., E.B., L.J.; supervision, G.J.W., L.J.; project administration, L.H., K.N., L.J.; funding acquisition, G.J.W., L.J.

**ACKNOWLEDGEMENTS**

We thank R. Aricescu and Y. Zhao (University of Oxford) for mammalian expression vector pHSec and cell line HEK293-T; D. de Sanctis (ESRF, Grenoble) for help with X-ray data collection; H. Monaco (University of Verona) for RIBP coordinates; other members of the Jovine laboratory for their initial involvement in the project; A. Stsiapanav (Karolinska Institutet) for comments. Research was supported by Karolinska Institutet; the Center for Innovative Medicine; Swedish Research Council grant 2012-5093; the Göran Gustafsson Foundation for Research in Natural Sciences and Medicine; the Sven and Ebba-Christina Hagberg foundation; an EMBO Young Investigator award; the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement 260759 (to L.J.); the Wellcome Trust grant number 098051 and the UK Medical Research Council grant MR/ M012468/1 (to G.J.W.).

**REFERENCES**

1. Bianchi, E., Doe, B., Goulding, D., and Wright G.J. (2014). Izumo is the egg Izumo receptor and is essential for mammalian fertilization. Nature 508, 483–487.
2. Wassarman, P.M. (2014). Reproductive biology: Sperm protein finds its mate. Nature 508, 486–487.
3. Inoue, N., Ikawa, M., Isotani, A., and Okabe, M. (2005). The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs. Nature 434, 234–238.
4. Chen, C., Ke, J., Zhou, X.E., Yi, W., Brunzelle, J.S., Li, J., Yong, E.L., Xu, H.E., and Melcher, K. (2013). Structural basis for molecular recognition of folic acid by folate receptors. Nature 500, 486–489.
5. Wilbowo, A.S., Singh, M., Reeder, K.M., Carter, J.J., Kovach, A.R., Meng, W., Ratnam, M., Zhang, F., and Dann, C.E. (2013). Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc. Natl. Acad. Sci. USA 110, 15180–15188.
6. Monaco, H.L. (1997). Crystal structure of chicken riboflavin-binding protein. EMBO J. 16, 1475–1483.
7. Bianchi, E., and Wright, G.J. (2015). Cross-species fertilization: the hamster egg receptor, Juno, binds the human sperm ligand, Izumo1. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140101.
8. Inoue, N., Hamada, D., Kamikubo, H., Hirata, K., Katoaka, K., Yamamoto, M., Ikawa, M., Okabe, M., and Hagihara, Y. (2013). Molecular dissection of IZUMO1, a sperm protein essential for sperm-egg fusion. Development 140, 3221–3229.
9. Kwon, H.J., Abi-Mosleh, L., Wang, M.L., Deisenhofer, J., Goldstein, J.L., Brown, M.S., and Infante, R.E. (2009). Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137, 1213–1224.

1Department of Biosciences and Nutrition & Center for Innovative Medicine, Karolinska Institutet, Huddinge, SE-141 83, Sweden.
2Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.
3Joint first authors.

E-mail: luca.jovine@ki.se

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Current Biology 26, R83–R101, February 8, 2016 ©2016 The Authors R101
Supplemental Information

Divergent evolution of vitamin B₉ binding underlies Juno-mediated adhesion of mammalian gametes

Ling Han, Kaoru Nishimura, Hamed Sadat Al Hosseini, Enrica Bianchi, Gavin J. Wright, and Luca Jovine
Figure S1
Figure S1. Characterization and structure determination of recombinant Juno.

(A) SDS-PAGE analysis of purified mouse Juno. The relative shift in migration between samples (4 μg) run under reducing (R) and non-reducing (NR) conditions is due to the presence of 8 conserved intramolecular disulfides bonds (Figure 1A and Figure S2A). MWM, molecular weight marker. (B) Analytical size-exclusion chromatography (SEC) analysis of purified Juno, whose elution volume ($V_e$) is consistent with a monomeric state. Arrows below the chromatogram mark the $V_e$ of protein standards of the indicated molecular weights (MW). (C) Juno crystal used for data collection. The size of the X-ray beam is indicated by the blue circle. (D) X-ray data collection and refinement statistics. (E) $2F_{\text{obs}} - DF_{\text{calc}}$ likelihood-weighted map (blue mesh) and feature-enhanced map (pink mesh) of the region around disulfides 1–3. Both electron density maps are uncarved and contoured at 1σ. (F) The GlcNAc residue attached to N185 of Juno molecule B (brown) interacts with W121 and L148 of the same molecule (light grey) and is involved in a crystal contact with a symmetry-related copy of chain B (dark grey). Maps are as in (E), but were carved around displayed residues for clarity. (G) Reducing anti-5His immunoblot of 20 μl conditioned medium of HEK293-T cells expressing fully glycosylated wt mouse Juno and different glycosylation mutants thereof.
Figure S2
Figure S2. Features of Juno and sequence/structure alignment to FRα and NPC1.

(A) Structure-based sequence alignment of Juno homologues and human FRα. Residues conserved between mouse and human Juno are highlighted in yellow; amino acids identical or similar in all sequences are bold or red, respectively. Secondary structure elements of mouse Juno and human FRα are indicated above and below the sequences, respectively, with core helices labelled as in Figure 1A. Conserved disulfide bonds 1–8 are indicated by pink lines, with corresponding cysteine pair numbers reported in the table on the bottom right. Juno disulfide bond 8 is not defined in the electron density, and has thus been assigned by exclusion and based on similarity with FRα. Juno N-glycosylation sites are indicated by inverted brown tripods, and regions corresponding to loop 1–3 as well as N185 are marked with boxes colored as in Figure 1B–D. Amino acids disordered in either Juno molecule A or B are indicated by an orange bar above their sequence, residues disordered in both Juno molecules are marked by a red bar. (B) Juno and NPC1 are structural homologues. Despite having only 12% sequence identity, the two molecules are clearly identified as being structurally similar by Dali (Z-score 7.5) and can be superimposed with an RMSD of 3.1 Å over 109 residues. The four core α-helices of Juno and the corresponding helices of NPC1 (PDB ID 3GKI [S1]) (α1: P52-L62; α3: C97-S114; α5: G149-R161; α7: Q185-F194) are shown in rainbow color; the extra helix of NPC1 (α2: D76-S95) is shown in purple, as in Figure 1E. For clarity, molecules have been translated relative to each other after superposition.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

DNA Constructs

Carboxy-terminally 8His-tagged Juno expression constructs for crystallographic studies were obtained by cloning synthetic genes (DNA2.0; GeneArt/Life Technologies) into pHLsec3H, a mammalian expression vector derived from pHLsec [S2]. Constructs expressing N-glycosylation site mutants of Juno were generated by overlap extension PCR with reverse-phase cartridge-purified oligonucleotides (SIGMA-ALDRICH) and PfuTurbo DNA polymerase (Agilent Technologies), followed by cloning into pHLsec3H and verification by DNA sequencing (Eurofins Genomics). Juno and Izumo1 ectodomain constructs for AVEXIS experiments were generated by cloning synthetic genes (GeneArt/Life Technologies) into expression vectors that encoded either biotinylated ‘baits’ or pentameric β-lactamase-tagged ‘preys’ [S3]. In mouse Juno loop mutants 1, 2 and 3, sequences encoding residues E67–T83, V111–Q118 and H138–P165 were replaced with the corresponding sequences of human Juno (encoding D67–M83, G111–E124 and R144–Q171, respectively). In mutant 4, the N-glycosylation site at position 185 of mouse Juno was inactivated by mutation to the corresponding residue of the human homolog (S191). DNA for transfection was prepared using HiSpeed Plasmid Midi kits or EndoFree Plasmid Giga kits (QIAGEN).
Protein Expression

For structural studies N-acetylglucosaminytransferase I-deficient (GnTI-) cell line Human Embryonic Kidney (HEK) 293-S (ATCC CRL-3022) was used, which secretes proteins carrying Endoglycosidase H (Endo H)-sensitive Man5GlcNAc2 N-glycans [S4,S5]. Cells were cultivated in Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (Saveen Werner) at 37ºC, 5% CO2. Transient transfections were performed in DMEM supplemented with 4 mM L-glutamine using 25 kDa branched polyethyleneimine (SIGMA-ALDRICH), essentially as described [S2]. Small- and large-scale transfections were carried out in 6-well plates (10 cm²/well; Corning) and cell factories (2528 cm²; Nunc), respectively. Proteins for N-glycosylation site analysis (Figure S1G) and AVEXIS assays (Figure 1C) were expressed using cell lines HEK293-T (a kind gift from R. Aricescu, University of Oxford) and HEK293-6E [S6], respectively.

Protein Purification

Secreted proteins were captured from conditioned medium by batch immobilized metal-affinity chromatography with Ni-NTA Superflow (QIAGEN). After Endo H treatment, proteins were subjected to SEC using a HiLoad 26/60 Superdex 75 column (GE Healthcare) equilibrated against 10 mM HEPES pH 7.8, 150 mM NaCl and finally concentrated to 6 mg/ml. Analysis of the oligomeric state of purified Juno (Figure S1A) was performed using a calibrated Superdex 75 10/300 GL analytical SEC column (GE Healthcare) (Figure S1B).
Western Blot Analysis

Immunoblot experiments were performed using Penta-His mouse monoclonal antibody (QIAGEN; 1:1000) and peroxidase-conjugate AffiniPure goat anti-mouse IgG (Jackson ImmunoResearch Lab; 1:10,000). Chemiluminescence detection was performed with Western Lightning ECL Plus (Perkin Elmer).

Protein Crystallization

Clusters of thin rod-shaped crystals (~200 μm long) were grown by vapor diffusion against mother liquor containing 200 mM CaCl₂, 100 mM Tris-HCl pH 8.5, 25% (w/v) PEG 4000 at 20°C. Individual crystals were obtained by breaking clusters with a microtool, cryoprotected using mother liquor supplemented with 5% PEG 200 and 5% PEG 4000, mounted in MicroLoops (MiTeGen) and flash cooled in liquid nitrogen prior to data collection at 100 K.

X-ray Diffraction Data Collection, Processing and Structure Determination

Of more than one hundred crystals screened at synchrotron, only one specimen (Figure S1C) yielded usable X-ray diffraction data (Figure S1D). This was collected using a PILATUS 6M-F detector (DECTRIS) at European Synchrotron Radiation Facility (ESRF) beamline ID29 [S7]. Integration and scaling were performed with XDS [S8], using CC(1/2) = 0.5 as high resolution cutoff criterion [S9]. A search ensemble for molecular replacement (MR) was generated using MrBUMP [S10], based on chains E–H of human FRα (PDB ID 4LRH; 52.7% sequence identity to Juno) [S11]. A single MR solution with
one molecule per asymmetric unit was found by PHASER [S12] in space group \(P2_12_12\) (translation function Z-score 17.0), which was autotraced with PHENIX AutoBuild [S13] and manually rebuilt in Coot [S14]. Refinement of the resulting model with phenix.refine [S15] could however not proceed beyond \(R_{\text{free}} \sim 32.5\%\). This suggested that the initial space group assignment was incorrect, and that the crystal belonged to space group \(P2_1\) with \(\beta \sim 90^\circ\) and a high merohedral twin fraction that mimicked primitive orthorhombic symmetry. Refinement of the model in \(P2_1\), with twinning operator \(h, -k, -l\) and two molecules of Juno per asymmetric unit, yielded a final \(R_{\text{free}}\) value of 24.8\% (Figure S1D). Chains A and B of the final model contain 166 and 172 amino acids, respectively. Juno residues G20, Q35–E40, E67–H78, P112–E117, D152–P165 of molecule A and G20–K22, G38–E42, L71–L81, W151–P165 of molecule B are not defined in the electron density map (Figure S2A); molecule A L43 and molecule B R194 also have very poor density, but were modelled because their position is constrained by the neighboring, well-defined residues. Feature-enhanced maps were used for rebuilding in addition to conventional \(\sigma A\)-weighted maps [S16]; protein geometry was validated with MolProbity [S17] and carbohydrate structure validation was carried out using Privateer [S18]. Structure comparisons were performed using PDBeFold [S19], pairwise DaliLite [S20] and the Dali server [S21]. Structural figures were prepared with PyMOL (Schrödinger); the alignment in Figure S2A was generated using ESPript [S22]. Structure factor intensities and atomic coordinates have been deposited in the Protein Data Bank with accession code 5EJN.
**Juno-Izumo1 Interaction Assay by AVEXIS**

AVEXIS assays were performed essentially as described [S23]. Briefly, biotinylated baits were extensively dialyzed against PBS and both baits and preys were normalized as previously described [S24]. Biotinylated baits were immobilized in streptavidin-coated 96-well microtitre plates (NUNC) and washed, after which normalized preys were added and incubated for one hour. After washing three times with PBS/0.1% Tween-20, 1X PBS, colorimetric β-lactamase substrate nitrocefin was added at 125 µg/ml. Absorbance values were measured at 485 nm on a Pherastar plus (BMG Laboratories). A representative of four experiments is shown in Figure 1C, and the same conclusions were reached from an independent experiment where bait-prey orientations were reversed.
SUPPLEMENTAL REFERENCES

S1. Kwon H.J., Abi-Mosleh L., Wang M.L., Deisenhofer J., Goldstein J.L., Brown M.S., and Infante R.E. (2009). Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137, 1213-1224.

S2. Aricescu A.R., Lu W., and Jones E.Y. (2006). A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243-1250.

S3. Sun Y., Gallagher-Jones M., Barker C., and Wright G.J. (2012). A benchmarked protein microarray-based platform for the identification of novel low-affinity extracellular protein interactions. Anal. Biochem. 424, 45-53.

S4. Reeves P.J., Callewaert N., Contreras R., and Khorana H.G. (2002). Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. USA 99, 13419-13424.

S5. Chang V.T., Crispin M., Aricescu A.R., Harvey D.J., Nettleship J.E., Fennelly J.A., Yu C., Boles K.S., Evans E.J., Stuart D.I., et al. (2007). Glycoprotein structural genomics: solving the glycosylation problem. Structure 15, 267-273.

S6. Loignon M., Perret S., Kelly J., Boulais D., Cass B., Bisson L., Afkhamizarreh F., and Durocher Y. (2008). Stable high volumetric production of glycosylated human recombinant IFNa2b in HEK293 cells. BMC Biotechnol. 8, 65.
S7. de Sanctis D., Beteva A., Caserotto H., Dobias F., Gabadinho J., Giraud T., Gobbo A., Guijarro M., Lentini M., Lavault B., et al. (2012). ID29: a high-intensity highly automated ESRF beamline for macromolecular crystallography experiments exploiting anomalous scattering. J. Synchrotron Radiat. 19, 455-461.

S8. Kabsch W. (2010). XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132.

S9. Evans P.R., and Murshudov G.N. (2013). How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214.

S10. Keegan R.M., and Winn M.D. (2008). MrBUMP: an automated pipeline for molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 64, 119-124.

S11. Chen C., Ke J., Zhou X.E., Yi W., Brunzelle J.S., Li J., Yong E.L., Xu H.E., and Melcher K. (2013). Structural basis for molecular recognition of folic acid by folate receptors. Nature 500, 486-489.

S12. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., and Read R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674.

S13. Terwilliger T.C., Grosse-Kunstleve R.W., Afonine P.V., Moriarty N.W., Zwart P.H., Hung L.W., Read R.J., and Adams P.D. (2008). Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D Biol. Crystallogr. 64, 61-69.

S14. Emsley P., Lohkamp B., Scott W.G., and Cowtan C. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501.
S15. Afonine P.V., Grosse-Kunstleve R.W., Echols N., Headd J.J., Moriarty N.W., Mustyakimov M., Terwilliger T.C., Urzhumtsev A., Zwart P.H., and Adams P.D. (2012). Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352-367.

S16. Afonine P.V., Moriarty N.W., Mustyakimov M., Sobolev O.V., Terwilliger T.C., Turk D., Urzhumtsev A., and Adams P.D. (2015). FEM: feature-enhanced map. Acta Crystallogr. D Biol. Crystallogr. 71, 646-666.

S17. Chen V.B., Arendall W.B., Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., Murray L.W., Richardson J.S., and Richardson D.C. (2010). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21.

S18. Agirre J., Iglesias-Fernandez J., Rovira C., Davies G.J., Wilson K.S., and Cowtan K.D. (2015). Privateer: software for the conformational validation of carbohydrate structures. Nat. Struct. Mol. Biol. 22, 833-834.

S19. Krissinel E., and Henrick K. (2005). Multiple Alignment of Protein Structures in Three Dimensions. In Lecture Notes in Computer Science, (Berlin, Heidelberg: Springer Berlin Heidelberg), pp. 67-78.

S20. Hasegawa H., and Holm L. (2009). Advances and pitfalls of protein structural alignment. Curr. Opin. Struct. Biol. 19, 341-348.

S21. Holm L., and Rosenstrom P. (2010). Dali server: conservation mapping in 3D. Nucleic Acids Res. 38, W545-W549.
S22. Gouet P., Robert X., and Courcelle E. (2003). ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res. 31, 3320-3323.

S23. Bushell K.M., Söllner C., Schuster-Boeckler B., Bateman A., and Wright G.J. (2008). Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res. 18, 622-630.

S24. Kerr J.S., and Wright G.J. (2012). Avidity-based extracellular interaction screening (AVEXIS) for the scalable detection of low-affinity extracellular receptor-ligand interactions. J. Vis. Exp. e3881.